The Netherlands
Salvia BioElectronics, established in 2017 and based in The Netherlands, is pioneering the field of bioelectronics with its focus on addressing chronic migraines. The company draws inspiration for its name from the Latin word salvere, meaning "to maintain good health", and the Salvia plant, known for its therapeutic properties.
Operating at the intersection of Biotechnology, Health and Wellness, and Medical Devices, Salvia aims to restore wellness in individuals plagued by persistent migraines through innovative bioelectronic solutions. This novel approach sets it apart in a growing market keen on non-pharmacological treatments.
The company recently secured a substantial €53.00M Series B funding on 27 May 2025, indicating strong investor confidence. Key investors include Invest-NL, Panakes Partners, SHS Capital, Thuja Capital, Inkef, Innovation Industries, EIC Fund, Dolby Family Ventures, and BOM, each bringing strategic value to Salvia's mission of pioneering health solutions. This investment will likely fuel expansion and accelerate product development, positioning Salvia BioElectronics as a transformative player in the treatment of migraines.
